LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Repros Therapeutics Inc. (“Repros” or the “Company”) (Nasdaq: RPRX).
If you purchased or otherwise acquired Repros shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Repros and certain of its officers and/or directors violated federal securities laws. On July 17, 2017, the Company revealed that it received preliminary feedback from the U.S. Food & Drug Administration (“FDA”) regarding its clinical development program for Proellex, its oral delivery mechanism for telapristone acetate. Repros said that “[t]he Proellex program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.” The Company added that “a much larger clinical trial, with associated time and cost requirements, would be necessary.” Following this news, Repros’ stock price dropped.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.